A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Here, we demonstrate a protocol to use 16α-[18F]-fluoro-17β-estradiol (18F-FES) positron emission tomography (PET) as a tool to visualize ERα expression in ERα-positive breast xenografts.

Abstract

To demonstrate how estrogen receptor alpha (ERα) positive breast cancer xenografts may be visualized in BALB/c nude mice using 16α-[18F]-fluoro-17β-estradiol (18F-FES) positron emission tomography (PET), ovariectomized BALB/c nude mice were injected with ERα-positive breast cancer cells (MCF-7, 3 × 106 cells; shoulder [n = 10] or 4th inguinal mammary fat pad [n = 10]) or ERα-negative breast cancer cells (MDA-MB-231, 1 × 106 cells; mammary fat pad [n = 5]). Mice harboring MCF-7 cells received subcutaneous injections of 20 µg of 17β-estradiol (20 µg/20 µL; corn oil:ethanol, 9:1) in the nape of their necks 2 days prior to cell injection, followed by daily injections five times per week for 5 weeks. Tumor volumes were measured according to the formula: (L*W2)/2 (L; length, W; width). Once tumor volumes reached approximately 100 mm3, 17β-estradiol injections were halted 2 days prior to mice receiving 18F-FES for PET imaging to avoid competitive binding with ERα. Upon 18F-FES administration via the lateral tail vein, PET/MRI was performed for 15 min at 1 h to 1.5 h post-injection. 18F-FES uptake was not observed in ERα-negative, MDA-MB-231 tumor-bearing mice. 18F-FES uptake was most pronounced in mice harboring MCF-7 tumors in the shoulder. In MCF-7 tumors grown in the inguinal mammary fat pad, 18F-FES uptake was less visible, as the intestinal excretion pattern of 18F-FES obscured the radioactivity detectable in these tumors. To use 18F-FES PET as a tool to visualize ERα expression in ERα-positive breast xenografts, we demonstrate that the visibility of 18F-FES uptake is clear in tumors located away from the abdominal region of mice, such as in the shoulder.

Introduction

Breast cancers (BC) can be stratified into different molecular subtypes1. Breast tumors that are classified as the luminal subtype overexpress estrogen receptor alpha (ERα). As such, this subtype of BC is also referred to as ERα-positive (ERα+). Fortunately, those diagnosed with ERα+ BC experience the highest 10-year survival coupled with low rates of distant metastasis2,3. Due to ERα expression, such patients have access to a collection of hormone therapy options, including selective estrogen receptor modulators (SERMs), anti-estrogen drug....

Protocol

All animal studies were approved by the Austin Hospital Animal Ethics Committee (A2023/05812) and conducted in compliance with the Australian Code for the care and use of animals for scientific purposes.

1. Cell preparation

  1. Using routine cell culture procedures, maintain MDA-MB-231 and MCF-7 cells in DMEM/F-12 supplemented with penicillin/streptomycin and 10% fetal bovine serum (FBS) in T175 tissue culture flasks. Prior to preparing cells for injection, passage cells at least 3x following revival from liquid nitrogen stores. Grow the cells in a humidified incubator at 37 °C with 5% CO2.

Representative Results

To determine the location for which ERα positive tumors can be clearly visualized using 18F-FES PET, three cohorts of ovariectomized mice were used in this study (Figure 1). Two groups of mice were injected with MCF-7 cells - an ERα positive breast cancer cell line - either IMF or in the shoulder. As a negative control, another cohort of mice was injected with MDA-MB-231 cells, a commonly used triple-negative breast cancer cell line that does not express ERα (

Discussion

Here, we describe the utility of 18F-FES PET/MRI in the detection of breast tumors characterized by ERα expression. As an example, we demonstrate that one location at which ERα positive tumors can be visualized is in the shoulder of mice - these tumors can be clearly identified by 18F-FES uptake, compared to tumors located within the 4th inguinal mammary fat pad (Figure 4). 18F-FES uptake was not visible in MDA-MB-231 tumors, confirming i.......

Disclosures

The authors have nothing to disclose.

Acknowledgements

This work was supported by the National Breast Cancer Foundation (IIRS-22-071). We acknowledge the Operational Infrastructure Support program of the Victorian State Government. This research was also undertaken using the Solid Target Laboratory, an ANSTO-Austin-LICR Partnership, also supported by the National Imaging Facility and the Victorian Government. The authors acknowledge the scientific and technical assistance of the National Imaging Facility, a National Collaborative Research Infrastructure Strategy (NCRIS) capability, at the La Trobe-ONJCRI node, Olivia Newton-John Cancer Research Institute (ONJCRI). Figures 1 and 3 have been made with BioRender.

....

Materials

NameCompanyCatalog NumberComments
2.5% Trypsin (10x)Gibco15090-046
27 G x 13 mm 0.5 mL insulin syringeTerumoSS*05M2713KAFor cell injections
29 G x 13 mm 0.5 mL insulin syringeTerumoSS*05M2913KAFor estradiol injections
30% H2O2Chem-SupplyHA154Diluted to a 3% working solution with distilled water
Corn oilSigmaC8267
DAB Substrate KitAbcamab64238
Dako anti-rabbit-HRP, 110 mLAligent-DakoK4003Secondary antibody used for IHC
DMEM/F-12 MediumGibco11320033
Dose calibratorCapintec5130-3216
Estradiol SigmaE2758
Estrogen Receptor α (D8H8) Rabbit mAbCell Signalling Technology#8644Primary antibody used for IHC
FBSBovogenSFBS
Heat element (Infra Red Lamp)Amcal12400For tail vein dilation
MatrigelCorning356225
MultiCell 4 Channel Monitoring kit for triple- or quadruple-mouse imaging chamberMedisoPR-MC900200For monitoring of mouse respiration
NanoScan PET/MRI 3T SystemMedisoPR-RD000000For PET/MRI acquistion
PBS (1x)Gibco14190-144
TBSTThermoFisher#28360Wash buffer for IHC
Three mice imaging chamberMedisoPR-MC407300For PET/MRI acquistion

References

  1. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature. 406 (6797), 747-752 (2000).
  2. Ignatov, A., Eggemann, H., Burger, E., Ignatov, T. Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol. 144 (7), 1347-1355 (2018).
  3. Siegel, R. L., Giaquinto, A. N., Jemal, A. Cancer statistics, 2024. CA Cancer J Clin. 74 (1), 12-49 (2024).
  4. Gnant, M., Turner, N. C., Hernando, C. Managing a long and winding road: Estrogen receptor-positive breast cancer. Am Soc Clin Oncol Educ Book. 43, e390922 (2023).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

Cancer Research

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved